US Edition
News from biopharmadive.com
Media Bias Ratings
Average Bias Rating:
Center
Center
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top biopharmadive.com News
FDA · United States(MedPage Today) -- The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer.
Approval was based on results...See the Story
AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment
80% Center coverage: 10 sources
FDA · United States(MedPage Today) -- Under a program designed to accelerate the approval of products that could address key national priorities, the FDA said it proactively awarded a national priority voucher to teclistamab (Tecvayli) in combination with daratumumab...See the Story
Myeloma Combination Cuts Line for FDA Approval After Strong ASH Results
71% Center coverage: 7 sources
